市場調查報告書

Liquid、活體組織切片的全球市場的未來預測

Global Liquid Biopsy Market Forecast 2019-2027

出版商 Inkwood Research 商品編碼 628608
出版日期 內容資訊 英文 224 Pages
商品交期: 2-3個工作天內
價格
Back to Top
Liquid、活體組織切片的全球市場的未來預測 Global Liquid Biopsy Market Forecast 2019-2027
出版日期: 2019年09月20日內容資訊: 英文 224 Pages
簡介

本報告提供全球液態活體組織切片 (液態生物檢體) 市場未來展望相關分析,技術概要和市場基本結構,主要的促進、阻礙因素,市場整體及各領域 (產品種類、目的、用戶等)、各地區的市場趨勢預測 (今後10年份),相關市場與的關聯性,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場決策要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 市場課題

第5章 市場區隔 (今後9年份)

  • 各產品的市場 (今後9年份)
    • 血中循環腫瘤細胞 (CTC)/血中循環腫瘤DNA (ctDNA)
    • 外吐小體
  • 各分析目的市場 (今後9年份)
    • 早期發現、篩檢
    • 治療指導
    • 監測
    • 診斷
  • 各終端用戶的市場 (今後9年份)
    • 開業醫生、診療所
    • 醫院
    • 臨床診斷用實驗室
  • 各分析平台的市場 (今後9年份)
    • NGS (次世代定序)
    • 微陣列
    • PCR (聚合酵素鏈鎖反應)
    • 蛋白質體學
    • 其他的企業
  • 生物標記的各種類的市場 (今後9年份)
    • 核酸
    • 蛋白質
    • 細胞外小胞
    • 細胞
  • 各適應症的市場
    • NIPT (非侵入性生產前檢驗)
    • 癌症
    • 移植

第6章 主要指標

  • 波特的五力分析
  • 液態切片的開發中產品
  • 專利分析
  • 市場趨勢
  • 液態切片相關的主要配合措施事項

第7章 各地區分析

  • 北美 (美國,加拿大)
  • 歐洲 (英國,法國,德國,義大利,西班牙,俄羅斯等)
  • 亞太地區 (日本,中國,印度,韓國等)
  • 其他的國家 (RoW:中東、北部非洲 (MENA),南美)

第8章 企業簡介

  • 競爭環境
  • AD-TECH MEDICAL INSTRUMENT CORP
  • AGILENT TECHNOLOGIES, INC.
  • ARGON MEDICAL DEVICES INC
  • B. BRAUN MELSUNGEN AG
  • BECTON, DICKINSON
  • BOSTON SCIENTIFIC CORPORATION
  • BIO-RAD LABORATORIES, INC.
  • C. R. BARD, INC.
  • CINTEC MEDICAL LTD
  • COOK GROUP INC
  • FISCHER MEDICAL TECHNOLOGIES LLC
  • I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
  • PLANMECA OY
  • ROCHE DIAGNOSTICS LTD
  • QIAGEN N.V.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 16840

KEY FINDINGS

Developments in precision medicines, increasing prevalence of cancer cases in the elderly population, and supportive government initiatives are some of the factors that are contributing to the expansion of the liquid biopsy market on a global scale. Over the estimated period of 2019-2027, the global liquid biopsy market is anticipated to rise at a CAGR of 21.04%, along with contributing $4957.3 million of revenue by the end of the period.

MARKET INSIGHTS

The global liquid biopsy market includes segments like biomarker types, analysis platform, products, clinical application, analysis purpose, therapeutic application, and end-users. The biomarker types include nucleic acids, proteins, extracellular vesicles, and cells. On the other hand, the analysis platform of this market includes Microarray, NGS, Proteomics, PCR, and other analysis platform. The Analysis purpose for this market is for therapy guidance, early detection/screening, monitoring, and diagnosis. The end-users for this market are Hospitals, Physicians' office laboratories, and clinical diagnostic laboratories.

REGIONAL INSIGHTS

The regional segmentation of the market is done into Europe, Asia Pacific, North America, and the rest of the world. The Asia Pacific liquid biopsy market is predicted to exhibit the fastest growth in the global market. Several vendors are favoring this market due to the easy availability of cheap labor, low raw-materials cost, and a large patient pool. The North American market is forecasted to dominate the global liquid biopsy market in the coming years owing to several technological advances in biopsy technologies. Canada and the US are the major contributors to this market.

COMPETITIVE INSIGHTS

The leading market players in the global liquid biopsy market are Ad-Tech Medical Instrument Corp, Becton, Dickinson, I.M.S. Internazionale Medico Scientifica Srl, Argon Medical Devices Inc., Boston Scientific Corporation, Qiagen N.V., Roche Diagnostics Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Planmeca Oy, C. R. Bard, Inc. (Acquired by Becton, Dickinson, and Company), Cintec Medical Ltd., Fischer Medical Technologies LLC, B. Braun Melsungen AG, and Cook Medical Inc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. LUNG CANCER IS THE MAJORLY USED THERAPEUTIC APPLICATION
    • 3.2.2. CELL-FREE DNA (CFDNA) AND CIRCULATING TUMOR DNA (CTDNA) ARE THE KEY PRODUCTS FOR LIQUID BIOPSY TESTS
    • 3.2.3. TREATMENT MONITORING IS THE WIDELY USED CLINICAL APPLICATION
    • 3.2.4. PCR IS THE FASTEST GROWING ANALYSIS PLATFORM
    • 3.2.5. EARLY DETECTION/SCREENING ANALYSIS PURPOSE CONSTITUTES THE LARGEST SHARE IN THE MARKET
    • 3.2.6. CLINICAL DIAGNOSTIC LABORATORIES ARE THE FASTEST GROWING END-USER DURING THE FORECAST PERIOD

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. RISING GOVERNMENT INITIATIVES
    • 4.2.2. GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
    • 4.2.3. GROWING NUMBER OF DIAGNOSTIC CENTERS
    • 4.2.4. GROWTH OF PRECISION MEDICINE
    • 4.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 4.2.6. RISING POTENTIAL OF THE LIQUID BIOPSY
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 4.3.2. POOR COMPENSATION STRUCTURES
    • 4.3.3. HIGH COST OF THE TEST
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. TECHNOLOGICAL ADVANCEMENT
    • 4.4.2. GROWING NUMBER OF CANCER PATIENTS
    • 4.4.3. EXPANSION IN THE EMERGING ECONOMIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LACK OF REIMBURSEMENT
    • 4.5.2. LACK OF SKILLED PROFESSIONALS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACIDS
  • 7.2. PROTEINS
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORM

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. KEY ANALYTICS

  • 12.1. PORTER'S FIVE FORCES MODEL
    • 12.1.1. THREAT OF NEW ENTRANTS
    • 12.1.2. THREAT OF SUBSTITUTES
    • 12.1.3. BARGAINING POWER OF BUYERS
    • 12.1.4. BARGAINING POWER OF SUPPLIERS
    • 12.1.5. THREAT OF RIVALRY
  • 12.2. PATENT ANALYSIS
  • 12.3. MARKET TRENDS
    • 12.3.1. NEW PLAYERS APPROACH VENTURE CAPITALISTS TO ENTER INTO NICHE MARKETS
    • 12.3.2. DIRECT-TO-CONSUMER TESTING
  • 12.4. KEY LIQUID BIOPSY INITIATIVES
  • 12.5. REGULATORY FRAMEWORK
  • 12.6. OPPORTUNITY MATRIX

13. GEOGRAPHICAL ANALYSIS

  • 13.1. NORTH AMERICA
    • 13.1.1. THE UNITED STATES
    • 13.1.2. CANADA
  • 13.2. EUROPE
    • 13.2.1. THE UNITED KINGDOM
    • 13.2.2. FRANCE
    • 13.2.3. GERMANY
    • 13.2.4. ITALY
    • 13.2.5. SPAIN
    • 13.2.6. RUSSIA
    • 13.2.7. REST OF EUROPE
  • 13.3. ASIA PACIFIC
    • 13.3.1. JAPAN
    • 13.3.2. CHINA
    • 13.3.3. INDIA
    • 13.3.4. SOUTH KOREA
    • 13.3.5. AUSTRALIA
    • 13.3.6. REST OF APAC
  • 13.4. REST OF WORLD
    • 13.4.1. MIDDLE EAST AND AFRICA (MEA)
    • 13.4.2. LATIN AMERICA

14. COMPANY PROFILES

  • 14.1. AD-TECH MEDICAL INSTRUMENT CORP
  • 14.2. AGILENT TECHNOLOGIES, INC.
  • 14.3. ARGON MEDICAL DEVICES INC.
  • 14.4. B. BRAUN MELSUNGEN AG
  • 14.5. BECTON, DICKINSON
  • 14.6. BOSTON SCIENTIFIC CORPORATION
  • 14.7. BIO-RAD LABORATORIES, INC.
  • 14.8. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON, AND COMPANY)
  • 14.9. CINTEC MEDICAL LTD.
  • 14.10. COOK MEDICAL INC.
  • 14.11. FISCHER MEDICAL TECHNOLOGIES LLC
  • 14.12. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
  • 14.13. PLANMECA OY
  • 14.14. ROCHE DIAGNOSTICS CORPORATION
  • 14.15. QIAGEN N.V.

LIST OF TABLES

  • TABLE 1 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
  • TABLE 3 GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 4 GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2019-2027 ($ MILLION)
  • TABLE 7 CELL DIFFERENTIATORS
  • TABLE 8 GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, 2019-2027 ($ MILLION)
  • TABLE 9 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 10 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 11 DROPLET DIGITAL PCR INDUSTRY
  • TABLE 12 GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL LIQUID BIOPSY MARKET, BY END-USER, 2019-2027 ($ MILLION)
  • TABLE 15 CTC-RELATED PATENTS
  • TABLE 16 CELL-FREE DNA-RELATED PATENTS
  • TABLE 17 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 18 NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 20 ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 21 REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 2 RURAL POPULATION IN DEVELOPING COUNTRIES 2017 (%)
  • FIGURE 3 GLOBAL LIQUID BIOPSY MARKET SHARE, BY THERAPEUTIC APPLICATION, 2018 & 2027 (%)
  • FIGURE 4 GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2019-2027 ($ MILLION)
  • FIGURE 5 TYPES OF BREAST CANCER
  • FIGURE 6 GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2018 & 2027 (%)
  • FIGURE 13 GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL LIQUID BIOPSY MARKET SHARE, BY BIOMARKER TYPE, 2018 & 2027 (%)
  • FIGURE 18 GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACIDS, 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL LIQUID BIOPSY MARKET, BY PROTEINS, 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2019-2027 ($ MILLION)
  • FIGURE 21 GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL LIQUID BIOPSY MARKET SHARE, BY ANALYSIS PLATFORM, 2018 & 2027 (%)
  • FIGURE 23 GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2019-2027 ($ MILLION)
  • FIGURE 24 GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2019-2027 ($ MILLION)
  • FIGURE 25 GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2019-2027 ($ MILLION)
  • FIGURE 26 GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2019-2027 ($ MILLION)
  • FIGURE 27 GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORM, 2019-2027 ($ MILLION)
  • FIGURE 28 GLOBAL LIQUID BIOPSY MARKET SHARE, BY ANALYSIS PURPOSE, 2018 & 2027 (%)
  • FIGURE 29 GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 30 GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2019-2027 ($ MILLION)
  • FIGURE 31 GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2019-2027 ($ MILLION)
  • FIGURE 32 GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2019-2027 ($ MILLION)
  • FIGURE 33 GLOBAL LIQUID BIOPSY MARKET SHARE, BY PRODUCT, 2018 & 2027 (%)
  • FIGURE 34 GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2019-2027 ($ MILLION)
  • FIGURE 35 GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2019-2027 ($ MILLION)
  • FIGURE 36 GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2019-2027 ($ MILLION)
  • FIGURE 37 GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2019-2027 ($ MILLION)
  • FIGURE 38 GLOBAL LIQUID BIOPSY MARKET SHARE, BY END-USER 2018 & 2027 (%)
  • FIGURE 39 GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2019-2027 ($ MILLION)
  • FIGURE 40 GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2019-2027 ($ MILLION)
  • FIGURE 41 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2019-2027 ($ MILLION)
  • FIGURE 42 PORTER'S FIVE FORCE MODEL
  • FIGURE 43 PATENTS FILED BY ASSIGNEE 2015-2018 (%)
  • FIGURE 44 GLOBAL LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2018 & 2027 (%)
  • FIGURE 45 NORTH AMERICA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 46 THE UNITED STATES LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 47 NEW CANCER CASES AND CANCER DEATHS IN THE US 2016-2020 (PER 100,000 POPULATION)
  • FIGURE 48 CANADA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 49 EUROPE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 50 THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 51 FRANCE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 52 GERMANY LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 53 ITALY LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 54 SPAIN LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 55 RUSSIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 56 REST OF EUROPE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 57 ASIA PACIFIC LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 58 JAPAN LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 59 CHINA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 60 INDIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 61 SOUTH KOREA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 62 AUSTRALIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 63 REST OF APAC LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 64 REST OF WORLD LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 65 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 66 NUMBER OF NEW CASES IN LATIN AMERICA AND THE CARIBBEAN 2018 (%)
  • FIGURE 67 LATIN AMERICA BIOPSY MARKET, 2019-2027 ($ MILLION)
Back to Top